PJSC Pharmaceutical Plant Egis (medicinal product: quality control, secondary packaging)

The drug is prescribed for the treatment of metastatic breast cancer (as monotherapy or in combination with other drugs), early-stage breast cancer, as well as metastatic gastric cancer or gastroesophageal junction cancer (in combination with other agents). In all cases, the presence of HER2 overexpression must be confirmed.

Dosage form: lyophilisate for concentrate for infusion solution

ATC: L01FD01